Lexicon Pharmaceuticals, Inc. Share Price
NASDAQ: LXRX | Small CapLexicon Pharmaceuticals, Inc. Stock Performance
Open $2.42 | Prev. Close $2.37 | Circuit Range N/A |
Day Range $2.29 - $2.48 | Year Range $1.02 - $2.68 | Volume 1,31,887 |
Average Traded $2.39 |
Lexicon Pharmaceuticals, Inc. Share Price Today
As of 10 August 2026, Lexicon Pharmaceuticals, Inc.'s share price is $2.46. The stock opened at $2.42, compared to its previous close of $2.37. During today's trading session, Lexicon Pharmaceuticals, Inc.'s share price traded between $2.29 and $2.48, with an average price of $2.38. Over the past 52 weeks, the stock has recorded a high of $2.68 and a low of $1.02. In terms of performance, Lexicon Pharmaceuticals, Inc.'s share price has risen by 67.01% over the last six months and is up 121.17% on a year-on-year basis.
Lexicon Pharmaceuticals, Inc. Share Price Chart
Lexicon Pharmaceuticals, Inc. Stock Fundamentals & Key Indicators
Market Cap $891.30M | PE Ratio (TTM) -17.54 | Dividend Yield N/A |
EPS (TTM) $-0.14 | Revenue (TTM) $45.00M | Return On Equity (TTM) -46.81% |
Profit Margin -111.87% | Debt to Equity 0.19 | Quarterly Earnings Growth YoY 80.30% |
Lexicon Pharmaceuticals, Inc. Quarterly Profit & Loss
All figures in USD
Lexicon Pharmaceuticals, Inc. Annual Profit & Loss
All figures in USD
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $2.29 | $2.46 | +6.74% |
Jul 2026 | $2.42 | $2.30 | -3.77% |
Jun 2026 | $2.16 | $2.39 | +9.38% |
May 2026 | $1.58 | $2.19 | +34.88% |
Apr 2026 | $1.59 | $1.62 | +3.85% |
Mar 2026 | $1.42 | $1.56 | +6.12% |
Feb 2026 | $1.14 | $1.47 | +27.83% |
Jan 2026 | $1.14 | $1.15 | +1.32% |
Dec 2025 | $1.38 | $1.14 | -20.63% |
Nov 2025 | $1.38 | $1.43 | +3.25% |
Oct 2025 | $1.41 | $1.39 | +2.59% |
Sep 2025 | $1.12 | $1.35 | +21.62% |
LXRX Share Price FAQs
What is Lexicon Pharmaceuticals, Inc. share price today?
What is the 52 week high and 52 week low of Lexicon Pharmaceuticals, Inc. stock?
What is LXRX's market capitalisation today?
What is LXRX's net income for the last quarter?
What is the 5 year returns of LXRX?
What is the high & low stock price of LXRX today?
Can I buy LXRX shares in India?